Recruiting

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

ClinicalTrials.gov IDNCT07271186

PhasePHASE2

Enrollment195

SponsorRegeneron Pharmaceuticals

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Diabetic Kidney Disease (DKD)

About this study

Interventions

Drug: ALN-ANG3 — Administered per the protocol
Drug: Evinacumab — No longer being administered
Drug: Placebo — Administered per the protocol

Primary outcomes

Percent Change in Urine Albumin to Creatinine Ratio (UACR) (Baseline to Week 24)

Eligibility information

Key Inclusion Criteria: 1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management 2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening 3. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening 4. Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening Key Exclusion Criteria: 1. Known medical history or clinical evidence indicative of non-diabetic renal disease 2. Renal disease that required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or kidney transplantation 3. Medically unstable as assessed by the investigator or hospitalization (ie, \>24 hours) within 30 days of the screening visit NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Study locations

Apogee Clinical Research, LLC, Huntsville, Alabama 35801 United States
Applied Research Center of Arkansas, Little Rock, Arkansas 72205 United States
AME Clinical Research, Huntington Beach, California 92647 United States
Amicis Research Center, Northridge, California 91325 United States
FOMAT - Vista del Mar Medical Group, Oxnard, California 93036 United States
Central Coast Nephrology, Salinas, California 93901 United States
North America Research Institute, San Dimas, California 91773 United States
Amicis Research Center, Santa Clarita, California 91355 United States
Valiance Clinical Research, Tarzana, California 91356 United States
Amicis Research Center, Valencia, California 91355 United States

Showing 10 of 58 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.